Opendata, web and dolomites
H2020 projects about "steatohepatitis"
The page lists 23 projects related to the topic "steatohepatitis".
| # | |||
|---|---|---|---|
| 1 | EPoS | Elucidating Pathways of Steatohepatitis | 2015 |
| 2 | FLDcure | A potent Micro-RNA therapeutic for nonalcoholic fatty liver disease (NAFLD) | 2015 |
| 3 | TARGEPILIVER | Characterization of Key Epigenetic Targets in Hepatic Fibrosis and Hepatocellular Carcinoma Development. Generation of New Antifibrotic and Antitumoral Drugs. | 2015 |
| 4 | Paediatric LMS | Non-Invasive Quantitative Magnetic Resonance for Obese Children – the Paediatric LiverMultiScan Test | 2015 |
| 5 | HEP-CAR | Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities. | 2016 |
| 6 | DeMILI | NON INVASIVE DIAGNOSTIC TEST SERVICE FOR “NON ALCOHOLIC FATTY LIVER DISEASE” MANAGEMENT | 2016 |
| 7 | HepatoMetaboPath | Cellular and molecular mechanisms of metabolic immune activation triggering non-alcoholic steatohepatitis (NASH) and HCC | 2016 |
| 8 | RADIcAL | Non-invasive rapid assessment of chronic liver disease using Magnetic Resonance Imaging with LiverMultiScan | 2016 |
| 9 | TGDNL | Mechanisms of cellular fatty acid homeostasis | 2017 |
| 10 | Foie Gras | Bioenergetic Remodeling in the Pathophysiology and Treatment of Non-Alcoholic Fatty Liver Disease | 2017 |
| 11 | EXNADMINA | EXercise as a regulator of hepatic NAD metabolism and MItochondrial function in Non-Alcoholic fatty liver disease | 2016 |
| 12 | mtFOIE GRAS | mitoFOIE GRAS: Non-invasive Profiling of Mitochondrial Function in Non-Alcoholic Fatty Liver Disease | 2017 |
| 13 | SULIPRO | A scientifically proven, safe, naturally derived drug for the effective treatment of liver damage - an innovative solution for a significant unmet medical need | 2017 |
| 14 | NAFLDcure | A novel pharmaceutical treatment for nonalcoholic fatty liver disease | 2017 |
| 15 | PRELICAN | Treatment of liver disease and cancer prevention | 2017 |
| 16 | HEPASPHER | Mimicking liver disease and regeneration in vitro for drug development and liver transplantation | 2017 |
| 17 | PhaseControl | How cellular suicide programmes control phase transitions in fatty liver disease and liver cancer | 2018 |
| 18 | HEPCAN | A Humanized Monoclonal Anti-Claudin1 Antibody (anti-CLDN1 mAb) for Treatment of Hepatocellular Carcinoma (HCC) | 2019 |
| 19 | CYPNASH | Validation of a novel class of cyclophilin inhibitors for the treatment of non-alcoholic steatohepatitis | 2019 |
| 20 | MyeFattyLiver | Unravelling the heterogeneity and functions of hepatic myeloid cells in Non-Alcoholic Fatty Liver Disease | 2019 |
| 21 | EU-PEARL | EU Patient- cEntric clinicAl tRial pLatform | 2019 |
| 22 | METABOLIGHT | Optical imaging platform to unravel metabolic reprogramming of cancer: a path for improved treatments | 2020 |
| 23 | MacinNASH | Revealing the contribution of liver macrophage populations to NASH in insulin resistance | 2020 |